The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A central review of liver resectability and pathological tumor response after chemotherapy in patients with initially unresectable colorectal cancer liver metastases: Phase II trials of mFOLFOX6 plus bevacizumab (KSCC0802), and SOX (S-1 and oxaliplatin) plus cetuximab (KSCC1002).
 
Eiji Oki
Speakers' Bureau - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
 
Yasunori Emi
No Relationships to Disclose
 
Hiroshi Saeki
No Relationships to Disclose
 
Shoji Tokunaga
No Relationships to Disclose
 
Toru Beppu
No Relationships to Disclose
 
Ken Shirabe
No Relationships to Disclose
 
Mitsuhisa Takatsuki
No Relationships to Disclose
 
Shinji Uchida
No Relationships to Disclose
 
Masahiko Sakoda
No Relationships to Disclose
 
Susumu Eguchi
No Relationships to Disclose
 
Masafumi Inomata
No Relationships to Disclose
 
Yoshito Akagi
No Relationships to Disclose
 
Shoji Natsugoe
No Relationships to Disclose
 
Yutaka Ogata
No Relationships to Disclose
 
Yoshihiro Kakeji
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Hideo Baba
Research Funding - Chugai Pharma (Inst)
 
Kenichi Iyama
No Relationships to Disclose
 
Yoshihiko Maehara
Patents, Royalties, Other Intellectual Property - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)